# OnCo record onchilles-pharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/onchilles-pharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "onchilles-pharma" ;
  schema:name "Onchilles Pharma"@en ;
  schema:alternateName "Onchilles Pharma Inc"@en ;
  schema:description "Onchilles Pharma makes N17350, an enzyme-based treatment injected into tumours that is designed to kill cancer cells while sparing immune cells, so the body's own defences can then attack the cancer. It is in an early trial in people with advanced solid tumours in the US and Australia."@en ;
  schema:url <https://onco.cc/companies/onchilles-pharma/>, <https://www.onchillespharma.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.onchillespharma.com/>, <https://www.onchillespharma.com/post/onchilles-pharma-announces-ind-clearance-for-n17350>, <https://www.onchillespharma.com/post/onchilles-pharma-doses-first-patient-in-phase-1-2-clinical-trial-of-n17350-for-advanced-solid-tumors>, <https://clinicaltrials.gov/study/NCT07339176> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/in-situ-vaccination/> ;
  onco:trials <https://onco.cc/trials/nct07339176/> .